Journal of Molecular Endocrinology

References

1. ↵
   1. Anderson KA,
   2. Ribar TJ,
   3. Lin F,
   4. Noeldner PK,
   5. Green MF,
   6. Muehlbauer MJ,
   7. Witters LA,
   8. Kemp BE &
   9. Means AR

   2008 Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metabolism 7 377–388.
2. ↵
   1. Andersson U,
   2. Filipsson K,
   3. Abbott CR,
   4. Woods A,
   5. Smith K,
   6. Bloom SR,
   7. Carling D &
   8. Small CJ

   2004 AMP-activated protein kinase plays a role in the control of food intake. Journal of Biological Chemistry 279 12005–12008.
3. ↵
   1. Andrews ZB,
   2. Liu ZW,
   3. Walllingford N,
   4. Erion DM,
   5. Borok E,
   6. Friedman JM,
   7. Tschop MH,
   8. Shanabrough M,
   9. Cline G,
   10. Shulman GI
   11. et al.

   2008 UCP-2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 454 846–851.
4. ↵
   1. Atkinson LL,
   2. Fischer MA &
   3. Lopaschuk GD

   2002 Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase–malonyl-CoA axis. Journal of Biological Chemistry 277 29424–29430.
5. ↵
   1. Banerjee RR,
   2. Rangwala SM,
   3. Shapiro JS,
   4. Rich AS,
   5. Rhoades B,
   6. Qi Y,
   7. Wang J,
   8. Rajala MW,
   9. Pocai A,
   10. Scherer PE
   11. et al.

   2004 Regulation of fasted blood glucose by resistin. Science 303 1195–1198.
6. ↵
   1. Barnes K,
   2. Ingram JC,
   3. Porras OH,
   4. Barros LF,
   5. Hudson ER,
   6. Fryer LG,
   7. Foufelle F,
   8. Carling D,
   9. Hardie DG &
   10. Baldwin SA

   2002 Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). Journal of Cell Science 115 2433–2442.
7. ↵
   1. Beg ZH,
   2. Allmann DW &
   3. Gibson DM

   1973 Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochemical and Biophysical Research Communications 54 1362–1369.
8. ↵
   1. Brabant G,
   2. Muller G,
   3. Horn R,
   4. Anderwald C,
   5. Roden M &
   6. Nave H

   2005 Hepatic leptin signaling in obesity. FASEB Journal 19 1048–1050.
9. ↵
   1. Brunmair B,
   2. Staniek K,
   3. Gras F,
   4. Scharf N,
   5. Althaym A,
   6. Clara R,
   7. Roden M,
   8. Gnaiger E,
   9. Nohl H,
   10. Waldhausl W
   11. et al.

   2004 Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53 1052–1059.
10. ↵
    1. Carling D

    2005 AMP-activated protein kinase: balancing the scales. Biochimie 87 87–91.
11. ↵
    1. Carling D

    2009 Branching out on AMPK regulation. Cell Metabolism 9 7–8.
12. ↵
    1. Carlson CA &
    2. Kim KH

    1973 Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. Journal of Biological Chemistry 248 378–380.
13. ↵
    1. Chau-Van C,
    2. Gamba M,
    3. Salvi R,
    4. Gaillard RC &
    5. Pralong FP

    2007 Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 148 507–511.
14. ↵
    1. Chen H,
    2. Montagnani M,
    3. Funahashi T,
    4. Shimomura I &
    5. Quon MJ

    2003 Adiponectin stimulates production of nitric oxide in vascular endothelial cells. Journal of Biological Chemistry 278 45021–45026.
15. ↵
    1. Christ-Crain M,
    2. Kola B,
    3. Lolli F,
    4. Fekete C,
    5. Seboek D,
    6. Wittmann G,
    7. Feltrin D,
    8. Igreja SC,
    9. Ajodha S,
    10. Harvey-White J
    11. et al.

    2008 AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal 22 1672–1683.
16. ↵
    1. Cool B,
    2. Zinker B,
    3. Chiou W,
    4. Kifle L,
    5. Cao N,
    6. Perham M,
    7. Dickinson R,
    8. Adler A,
    9. Gagne G,
    10. Iyengar R
    11. et al.

    2006 Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metabolism 3 403–416.
17. ↵
    1. Corton JM,
    2. Gillespie JG,
    3. Hawley SA &
    4. Hardie DG

    1995 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? European Journal of Biochemistry 229 558–565.
18. ↵
    1. Date Y,
    2. Shimbara T,
    3. Koda S,
    4. Toshinai K,
    5. Ida T,
    6. Murakami N,
    7. Miyazato M,
    8. Kokame K,
    9. Ishizuka Y,
    10. Ishida Y
    11. et al.

    2006 Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metabolism 4 323–331.
19. ↵
    1. Daval M,
    2. Diot-Dupuy F,
    3. Bazin R,
    4. Hainault I,
    5. Viollet B,
    6. Vaulont S,
    7. Hajduch E,
    8. Ferre P &
    9. Foufelle F

    2005 Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. Journal of Biological Chemistry 280 25250–25257.
20. ↵
    1. Derave W,
    2. Ai H,
    3. Ihlemann J,
    4. Witters LA,
    5. Kristiansen S,
    6. Richter EA &
    7. Ploug T

    2000 Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle. Diabetes 49 1281–1287.
21. ↵
    1. Di Marzo V,
    2. Goparaju SK,
    3. Wang L,
    4. Liu J,
    5. Batkai S,
    6. Jarai Z,
    7. Fezza F,
    8. Miura GI,
    9. Palmiter RD,
    10. Sugiura T
    11. et al.

    2001 Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 822–825.
22. ↵
    1. Di S,
    2. Malcher-Lopes R,
    3. Marcheselli VL,
    4. Bazan NG &
    5. Tasker JG

    2005 Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 146 4292–4301.
23. ↵
    1. Divertie GD,
    2. Jensen MD &
    3. Miles JM

    1991 Stimulation of lipolysis in humans by physiological hypercortisolemia. Diabetes 40 1228–1232.
24. ↵
    1. Djurhuus CB,
    2. Gravholt CH,
    3. Nielsen S,
    4. Mengel A,
    5. Christiansen JS,
    6. Schmitz OE &
    7. Moller N

    2002 Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. American Journal of Physiology. Endocrinology and Metabolism 283 E172–E177.
25. ↵
    1. El-Mir MY,
    2. Nogueira V,
    3. Fontaine E,
    4. Averet N,
    5. Rigoulet M &
    6. Leverve X

    2000 Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. Journal of Biological Chemistry 275 223–228.
26. ↵
    1. Febbraio MA

    2007 gp130 receptor ligands as potential therapeutic targets for obesity. Journal of Clinical Investigation 117 841–849.
27. ↵
    1. Fisher JS,
    2. Gao J,
    3. Han DH,
    4. Holloszy JO &
    5. Nolte LA

    2002 Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. American Journal of Physiology. Endocrinology and Metabolism 282 E18–E23.
28. ↵
    1. Foretz M,
    2. Ancellin N,
    3. Andreelli F,
    4. Saintillan Y,
    5. Grondin P,
    6. Kahn A,
    7. Thorens B,
    8. Vaulont S &
    9. Viollet B

    2005 Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54 1331–1339.
29. ↵
    1. Fryer LG,
    2. Parbu-Patel A &
    3. Carling D

    2002 The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. Journal of Biological Chemistry 277 25226–25232.
30. ↵
    1. Fu X,
    2. Wan S,
    3. Lyu YL,
    4. Liu LF &
    5. Qi H

    2008 Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS ONE 3 e2008.
31. ↵
    1. Gauthier MS,
    2. Miyoshi H,
    3. Souza SC,
    4. Cacicedo JM,
    5. Saha AK,
    6. Greenberg AS &
    7. Ruderman NB

    2008 AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. Journal of Biological Chemistry 283 16514–16524.
32. ↵
    1. Goldstone AP,
    2. Morgan I,
    3. Mercer JG,
    4. Morgan DG,
    5. Moar KM,
    6. Ghatei MA &
    7. Bloom SR

    2000 Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochemical and Biophysical Research Communications 269 331–335.
33. ↵
    1. Haque MS,
    2. Minokoshi Y,
    3. Hamai M,
    4. Iwai M,
    5. Horiuchi M &
    6. Shimazu T

    1999 Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Diabetes 48 1706–1712.
34. ↵
    1. Hardie DG,
    2. Salt IP,
    3. Hawley SA &
    4. Davies SP

    1999 AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochemical Journal 338 717–722.
35. ↵
    1. Harrington LS,
    2. Findlay GM,
    3. Gray A,
    4. Tolkacheva T,
    5. Wigfield S,
    6. Rebholz H,
    7. Barnett J,
    8. Leslie NR,
    9. Cheng S,
    10. Shepherd PR
    11. et al.

    2004 The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. Journal of Cell Biology 166 213–223.
36. ↵
    1. Hawley SA,
    2. Boudeau J,
    3. Reid JL,
    4. Mustard KJ,
    5. Udd L,
    6. Makela TP,
    7. Alessi DR &
    8. Hardie DG

    2003 Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. Journal of Biology 2 28.
37. ↵
    1. Hawley SA,
    2. Pan DA,
    3. Mustard KJ,
    4. Ross L,
    5. Bain J,
    6. Edelman AM,
    7. Frenguelli BG &
    8. Hardie DG

    2005 Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metabolism 2 9–19.
38. ↵
    1. Hayes MR,
    2. Bradley L &
    3. Grill HJ

    2009a Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 150 2654–2659.
39. ↵
    1. Hayes MR,
    2. Skibicka KP,
    3. Bence KK &
    4. Grill HJ

    2009b Dorsal hindbrain 5′-adenosine monophosphate-activated protein kinase as an intracellular mediator of energy balance. Endocrinology 150 2175–2182.
40. ↵
    1. Holmes BF,
    2. Kurth-Kraczek EJ &
    3. Winder WW

    1999 Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. Journal of Applied Physiology 87 1990–1995.
41. ↵
    1. Horman S,
    2. Vertommen D,
    3. Heath R,
    4. Neumann D,
    5. Mouton V,
    6. Woods A,
    7. Schlattner U,
    8. Wallimann T,
    9. Carling D,
    10. Hue L
    11. et al.

    2006 Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. Journal of Biological Chemistry 281 5335–5340.
42. ↵
    1. Hurley RL,
    2. Anderson KA,
    3. Franzone JM,
    4. Kemp BE,
    5. Means AR &
    6. Witters LA

    2005 The Ca²⁺/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. Journal of Biological Chemistry 280 29060–29066.
43. ↵
    1. Huypens P,
    2. Moens K,
    3. Heimberg H,
    4. Ling Z,
    5. Pipeleers D &
    6. Van de Casteele M

    2005 Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sciences 77 1273–1282.
44. ↵
    1. Inoki K,
    2. Zhu T &
    3. Guan KL

    2003 TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 577–590.
45. ↵
    1. Isomaa B,
    2. Almgren P,
    3. Tuomi T,
    4. Forsen B,
    5. Lahti K,
    6. Nissen M,
    7. Taskinen MR &
    8. Groop L

    2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 683–689.
46. ↵
    1. Kadowaki T,
    2. Yamauchi T &
    3. Kubota N

    2008 The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Letters 582 74–80.
47. ↵
    1. Kahn BB,
    2. Alquier T,
    3. Carling D &
    4. Hardie DG

    2005 AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 1 15–25.
48. ↵
    1. Kamohara S,
    2. Burcelin R,
    3. Halaas JL,
    4. Friedman JM &
    5. Charron MJ

    1997 Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389 374–377.
49. ↵
    1. Kefas BA,
    2. Cai Y,
    3. Kerckhofs K,
    4. Ling Z,
    5. Martens G,
    6. Heimberg H,
    7. Pipeleers D &
    8. Van de Casteele M

    2004 Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochemical Pharmacology 68 409–416.
50. ↵
    1. Keller C,
    2. Steensberg A,
    3. Pilegaard H,
    4. Osada T,
    5. Saltin B,
    6. Pedersen BK &
    7. Neufer PD

    2001 Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB Journal 15 2748–2750.
51. ↵
    1. Kelly M,
    2. Keller C,
    3. Avilucea PR,
    4. Keller P,
    5. Luo Z,
    6. Xiang X,
    7. Giralt M,
    8. Hidalgo J,
    9. Saha AK,
    10. Pedersen BK
    11. et al.

    2004 AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochemical and Biophysical Research Communications 320 449–454.
52. ↵
    1. Kim MS,
    2. Namkoong C,
    3. Kim HS,
    4. Jang PG,
    5. Kim Pak YM,
    6. Katakami H,
    7. Park JY &
    8. Lee KU

    2004a Chronic central administration of ghrelin reverses the effects of leptin. International Journal of Obesity and Related Metabolic Disorders 28 1264–1271.
53. ↵
    1. Kim MS,
    2. Park JY,
    3. Namkoong C,
    4. Jang PG,
    5. Ryu JW,
    6. Song HS,
    7. Yun JY,
    8. Namgoong IS,
    9. Ha J,
    10. Park IS
    11. et al.

    2004b Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nature Medicine 10 727–733.
54. ↵
    1. Kim JY,
    2. van de Wall E,
    3. Laplante M,
    4. Azzara A,
    5. Trujillo ME,
    6. Hofmann SM,
    7. Schraw T,
    8. Durand JL,
    9. Li H,
    10. Li G
    11. et al.

    2007 Obesity-associated improvements in metabolic profile through expansion of adipose tissue. Journal of Clinical Investigation 117 2621–2637.
55. ↵
    1. Kirkham TC,
    2. Williams CM,
    3. Fezza F &
    4. Di Marzo V

    2002 Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology 136 550–557.
56. ↵
    1. Kohno D,
    2. Gao HZ,
    3. Muroya S,
    4. Kikuyama S &
    5. Yada T

    2003 Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca²⁺ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 52 948–956.
57. ↵
    1. Kohno D,
    2. Sone H,
    3. Minokoshi Y &
    4. Yada T

    2008 Ghrelin raises [Ca²⁺]_i via AMPK in hypothalamic arcuate nucleus NPY neurons. Biochemical and Biophysical Research Communications 366 388–392.
58. ↵
    1. Kokoeva MV,
    2. Yin H &
    3. Flier JS

    2005 Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 310 679–683.
59. ↵
    1. Kola B

    2008 Role of AMP-activated protein kinase in the control of appetite. Journal of Neuroendocrinology 20 942–951.
60. ↵
    1. Kola B,
    2. Hubina E,
    3. Tucci SA,
    4. Kirkham TC,
    5. Garcia EA,
    6. Mitchell SE,
    7. Williams LM,
    8. Hawley SA,
    9. Hardie DG,
    10. Grossman AB
    11. et al.

    2005 Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. Journal of Biological Chemistry 280 25196–25201.
61. ↵
    1. Kola B,
    2. Farkas I,
    3. Christ-Crain M,
    4. Wittmann G,
    5. Lolli F,
    6. Amin F,
    7. Harvey-White J,
    8. Liposits Z,
    9. Kunos G,
    10. Grossman AB
    11. et al.

    2008 The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 3 e1797.
62. ↵
    1. Koo SH,
    2. Flechner L,
    3. Qi L,
    4. Zhang X,
    5. Screaton RA,
    6. Jeffries S,
    7. Hedrick S,
    8. Xu W,
    9. Boussouar F,
    10. Brindle P
    11. et al.

    2005 The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437 1109–1111.
63. ↵
    1. Kovacic S,
    2. Soltys CL,
    3. Barr AJ,
    4. Shiojima I,
    5. Walsh K &
    6. Dyck JR

    2003 Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. Journal of Biological Chemistry 278 39422–39427.
64. ↵
    1. Kramer HF,
    2. Witczak CA,
    3. Fujii N,
    4. Jessen N,
    5. Taylor EB,
    6. Arnolds DE,
    7. Sakamoto K,
    8. Hirshman MF &
    9. Goodyear LJ

    2006 Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes 55 2067–2076.
65. ↵
    1. Kubota N,
    2. Yano W,
    3. Kubota T,
    4. Yamauchi T,
    5. Itoh S,
    6. Kumagai H,
    7. Kozono H,
    8. Takamoto I,
    9. Okamoto S,
    10. Shiuchi T
    11. et al.

    2007 Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metabolism 6 55–68.
66. ↵
    1. Kurth-Kraczek EJ,
    2. Hirshman MF,
    3. Goodyear LJ &
    4. Winder WW

    1999 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48 1667–1671.
67. ↵
    1. Leclerc I,
    2. Woltersdorf WW,
    3. da Silva Xavier G,
    4. Rowe RL,
    5. Cross SE,
    6. Korbutt GS,
    7. Rajotte RV,
    8. Smith R &
    9. Rutter GA

    2004 Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. American Journal of Physiology. Endocrinology and Metabolism 286 E1023–E1031.
68. ↵
    1. Lee Y,
    2. Naseem RH,
    3. Duplomb L,
    4. Park BH,
    5. Garry DJ,
    6. Richardson JA,
    7. Schaffer JE &
    8. Unger RH

    2004 Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. PNAS 101 13624–13629.
69. ↵
    1. Lessard SJ,
    2. Chen ZP,
    3. Watt MJ,
    4. Hashem M,
    5. Reid JJ,
    6. Febbraio MA,
    7. Kemp BE &
    8. Hawley JA

    2006 Chronic rosiglitazone treatment restores AMPKα2 activity in insulin-resistant rat skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism 290 E251–E257.
70. ↵
    1. Liao Y,
    2. Takashima S,
    3. Maeda N,
    4. Ouchi N,
    5. Komamura K,
    6. Shimomura I,
    7. Hori M,
    8. Matsuzawa Y,
    9. Funahashi T &
    10. Kitakaze M

    2005 Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovascular Research 67 705–713.
71. ↵
    1. Lochhead PA,
    2. Salt IP,
    3. Walker KS,
    4. Hardie DG &
    5. Sutherland C

    2000 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49 896–903.
72. ↵
    1. Lopez M,
    2. Lelliott CJ &
    3. Vidal-Puig A

    2007 Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. BioEssays 29 248–261.
73. ↵
    1. Lopez M,
    2. Lage R,
    3. Saha AK,
    4. Perez-Tilve D,
    5. Vazquez MJ,
    6. Varela L,
    7. Sangiao-Alvarellos S,
    8. Tovar S,
    9. Raghay K,
    10. Rodriguez-Cuenca S
    11. et al.

    2008 Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metabolism 7 389–399.
74. ↵
    1. McBride A,
    2. Ghilagaber S,
    3. Nikolaev A &
    4. Hardie DG

    2009 The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. Cell Metabolism 9 23–34.
75. ↵
    1. Merrill GF,
    2. Kurth EJ,
    3. Hardie DG &
    4. Winder WW

    1997 AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. American Journal of Physiology 273 E1107–E1112.
76. ↵
    1. Miller RG,
    2. Petajan JH,
    3. Bryan WW,
    4. Armon C,
    5. Barohn RJ,
    6. Goodpasture JC,
    7. Hoagland RJ,
    8. Parry GJ,
    9. Ross MA &
    10. Stromatt SC

    1996 A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Annals of Neurology 39 256–260.
77. ↵
    1. Miller EJ,
    2. Li J,
    3. Leng L,
    4. McDonald C,
    5. Atsumi T,
    6. Bucala R &
    7. Young LH

    2008 Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451 578–582.
78. ↵
    1. Minokoshi Y,
    2. Haque MS &
    3. Shimazu T

    1999 Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes 48 287–291.
79. ↵
    1. Minokoshi Y,
    2. Kim YB,
    3. Peroni OD,
    4. Fryer LG,
    5. Muller C,
    6. Carling D &
    7. Kahn BB

    2002 Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 339–343.
80. ↵
    1. Minokoshi Y,
    2. Alquier T,
    3. Furukawa N,
    4. Kim YB,
    5. Lee A,
    6. Xue B,
    7. Mu J,
    8. Foufelle F,
    9. Ferre P,
    10. Birnbaum MJ
    11. et al.

    2004 AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428 569–574.
81. ↵
    1. Momcilovic M,
    2. Hong SP &
    3. Carlson M

    2006 Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. Journal of Biological Chemistry 281 25336–25343.
82. ↵
    1. Mountjoy PD,
    2. Bailey SJ &
    3. Rutter GA

    2007 Inhibition by glucose or leptin of hypothalamic neurons expressing neuropeptide Y requires changes in AMP-activated protein kinase activity. Diabetologia 50 168–177.
83. ↵
    1. Muse ED,
    2. Obici S,
    3. Bhanot S,
    4. Monia BP,
    5. McKay RA,
    6. Rajala MW,
    7. Scherer PE &
    8. Rossetti L

    2004 Role of resistin in diet-induced hepatic insulin resistance. Journal of Clinical Investigation 114 232–239.
84. ↵
    1. Namkoong C,
    2. Kim MS,
    3. Jang PG,
    4. Han SM,
    5. Park HS,
    6. Koh EH,
    7. Lee WJ,
    8. Kim JY,
    9. Park IS,
    10. Park JY
    11. et al.

    2005 Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. Diabetes 54 63–68.
85. ↵
    1. Owen MR,
    2. Doran E &
    3. Halestrap AP

    2000 Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal 348 607–614.
86. ↵
    1. Palanivel R &
    2. Sweeney G

    2005 Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. FEBS Letters 579 5049–5054.
87. ↵
    1. Park H,
    2. Kaushik VK,
    3. Constant S,
    4. Prentki M,
    5. Przybytkowski E,
    6. Ruderman NB &
    7. Saha AK

    2002 Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. Journal of Biological Chemistry 277 32571–32577.
88. ↵
    1. Perrin C,
    2. Knauf C &
    3. Burcelin R

    2004 Intracerebroventricular infusion of glucose, insulin, and the adenosine monophosphate-activated kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside, controls muscle glycogen synthesis. Endocrinology 145 4025–4033.
89. ↵
    1. Qi J,
    2. Gong J,
    3. Zhao T,
    4. Zhao J,
    5. Lam P,
    6. Ye J,
    7. Li JZ,
    8. Wu J,
    9. Zhou HM &
    10. Li P

    2008 Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue. EMBO Journal 27 1537–1548.
90. ↵
    1. Ruderman NB,
    2. Keller C,
    3. Richard AM,
    4. Saha AK,
    5. Luo Z,
    6. Xiang X,
    7. Giralt M,
    8. Ritov VB,
    9. Menshikova EV,
    10. Kelley DE
    11. et al.

    2006 Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 55 S48–S54.
91. ↵
    1. Russell RR III.,
    2. Li J,
    3. Coven DL,
    4. Pypaert M,
    5. Zechner C,
    6. Palmeri M,
    7. Giordano FJ,
    8. Mu J,
    9. Birnbaum MJ &
    10. Young LH

    2004 AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. Journal of Clinical Investigation 114 495–503.
92. ↵
    1. Samaha FF,
    2. Szapary PO,
    3. Iqbal N,
    4. Williams MM,
    5. Bloedon LT,
    6. Kochar A,
    7. Wolfe ML &
    8. Rader DJ

    2006 Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 26 624–630.
93. ↵
    1. Sanders MJ,
    2. Grondin PO,
    3. Hegarty BD,
    4. Snowden MA &
    5. Carling D

    2007 Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochemical Journal 403 139–148.
94. ↵
    1. Seo S,
    2. Ju S,
    3. Chung H,
    4. Lee D &
    5. Park S

    2008 Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocrine Journal 55 867–874.
95. ↵
    1. Shah OJ,
    2. Wang Z &
    3. Hunter T

    2004 Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Current Biology 14 1650–1656.
96. ↵
    1. Shaw RJ,
    2. Kosmatka M,
    3. Bardeesy N,
    4. Hurley RL,
    5. Witters LA,
    6. DePinho RA &
    7. Cantley LC

    2004 The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. PNAS 101 3329–3335.
97. ↵
    1. Shaw RJ,
    2. Lamia KA,
    3. Vasquez D,
    4. Koo SH,
    5. Bardeesy N,
    6. Depinho RA,
    7. Montminy M &
    8. Cantley LC

    2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 1642–1646.
98. ↵
    1. Shibata R,
    2. Sato K,
    3. Pimentel DR,
    4. Takemura Y,
    5. Kihara S,
    6. Ohashi K,
    7. Funahashi T,
    8. Ouchi N &
    9. Walsh K

    2005 Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nature Medicine 11 1096–1103.
99. ↵
    1. Sleeman MW &
    2. Latres E

    2008 The CAMplexities of central ghrelin. Cell Metabolism 7 361–362.
100. ↵
     1. Steinberg GR,
     2. Rush JW &
     3. Dyck DJ

     2003 AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. American Journal of Physiology. Endocrinology and Metabolism 284 E648–E654.
101. ↵
     1. Steinberg GR,
     2. Michell BJ,
     3. van Denderen BJ,
     4. Watt MJ,
     5. Carey AL,
     6. Fam BC,
     7. Andrikopoulos S,
     8. Proietto J,
     9. Gorgun CZ,
     10. Carling D
     11. et al.

     2006a Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metabolism 4 465–474.
102. ↵
     1. Steinberg GR,
     2. Watt MJ,
     3. Fam BC,
     4. Proietto J,
     5. Andrikopoulos S,
     6. Allen AM,
     7. Febbraio MA &
     8. Kemp BE

     2006b Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology 147 3906–3914.
103. ↵
     1. Takekoshi K,
     2. Fukuhara M,
     3. Quin Z,
     4. Nissato S,
     5. Isobe K,
     6. Kawakami Y &
     7. Ohmori H

     2006 Long-term exercise stimulates adenosine monophosphate-activated protein kinase activity and subunit expression in rat visceral adipose tissue and liver. Metabolism 55 1122–1128.
104. ↵
     1. Tang CH,
     2. Chiu YC,
     3. Tan TW,
     4. Yang RS &
     5. Fu WM

     2007 Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. Journal of Immunology 179 5483–5492.
105. ↵
     1. Tataranni PA,
     2. Larson DE,
     3. Snitker S,
     4. Young JB,
     5. Flatt JP &
     6. Ravussin E

     1996 Effects of glucocorticoids on energy metabolism and food intake in humans. American Journal of Physiology 271 E317–E325.
106. ↵
     1. Terada S,
     2. Goto M,
     3. Kato M,
     4. Kawanaka K,
     5. Shimokawa T &
     6. Tabata I

     2002 Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. Biochemical and Biophysical Research Communications 296 350–354.
107. ↵
     1. Theander-Carrillo C,
     2. Wiedmer P,
     3. Cettour-Rose P,
     4. Nogueiras R,
     5. Perez-Tilve D,
     6. Pfluger P,
     7. Castaneda TR,
     8. Muzzin P,
     9. Schurmann A,
     10. Szanto I
     11. et al.

     2006 Ghrelin action in the brain controls adipocyte metabolism. Journal of Clinical Investigation 116 1983–1993.
108. ↵
     1. Tomas E,
     2. Tsao TS,
     3. Saha AK,
     4. Murrey HE,
     5. Zhang CcC,
     6. Itani SI,
     7. Lodish HF &
     8. Ruderman NB

     2002 Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. PNAS 99 16309–16313.
109. ↵
     1. Towler MC &
     2. Hardie DG

     2007 AMP-activated protein kinase in metabolic control and insulin signaling. Circulation Research 100 328–341.
110. ↵
     1. Treebak JT,
     2. Glund S,
     3. Deshmukh A,
     4. Klein DK,
     5. Long YC,
     6. Jensen TE,
     7. Jorgensen SB,
     8. Viollet B,
     9. Andersson L,
     10. Neumann D
     11. et al.

     2006 AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits. Diabetes 55 2051–2058.
111. ↵
     1. Trevisan M,
     2. Liu J,
     3. Bahsas FB &
     4. Menotti A

     1998 Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. American Journal of Epidemiology 148 958–966.
112. ↵
     1. Turnley AM,
     2. Stapleton D,
     3. Mann RJ,
     4. Witters LA,
     5. Kemp BE &
     6. Bartlett PF

     1999 Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. Journal of Neurochemistry 72 1707–1716.
113. ↵
     1. Um SH,
     2. Frigerio F,
     3. Watanabe M,
     4. Picard F,
     5. Joaquin M,
     6. Sticker M,
     7. Fumagalli S,
     8. Allegrini PR,
     9. Kozma SC,
     10. Auwerx J
     11. et al.

     2004 Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 200–205.
114. ↵
     1. Vazquez MJ,
     2. Gonzalez CR,
     3. Varela L,
     4. Lage R,
     5. Tovar S,
     6. Sangiao-Alvarellos S,
     7. Williams LM,
     8. Vidal-Puig A,
     9. Nogueiras R,
     10. Lopez M
     11. et al.

     2008 Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology 149 4534–4543.
115. ↵
     1. Viana AY,
     2. Sakoda H,
     3. Anai M,
     4. Fujishiro M,
     5. Ono H,
     6. Kushiyama A,
     7. Fukushima Y,
     8. Sato Y,
     9. Oshida Y,
     10. Uchijima Y
     11. et al.

     2006 Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Research and Clinical Practice 73 135–142.
116. ↵
     1. Witters LA

     2001 The blooming of the French lilac. Journal of Clinical Investigation 108 1105–1107.
117. ↵
     1. Wojtaszewski JF,
     2. Jorgensen SB,
     3. Hellsten Y,
     4. Hardie DG &
     5. Richter EA

     2002 Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes 51 284–292.
118. ↵
     1. Woods A,
     2. Azzout-Marniche D,
     3. Foretz M,
     4. Stein SC,
     5. Lemarchand P,
     6. Ferre P,
     7. Foufelle F &
     8. Carling D

     2000 Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Molecular and Cellular Biology 20 6704–6711.
119. ↵
     1. Woods A,
     2. Johnstone SR,
     3. Dickerson K,
     4. Leiper FC,
     5. Fryer LG,
     6. Neumann D,
     7. Schlattner U,
     8. Wallimann T,
     9. Carlson M &
     10. Carling D

     2003 LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Current Biology 13 2004–2008.
120. ↵
     1. Woods A,
     2. Dickerson K,
     3. Heath R,
     4. Hong SP,
     5. Momcilovic M,
     6. Johnstone SR,
     7. Carlson M &
     8. Carling D

     2005 Ca²⁺/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metabolism 2 21–33.
121. ↵
     1. Wright DC,
     2. Geiger PC,
     3. Holloszy JO &
     4. Han DH

     2005 Contraction- and hypoxia-stimulated glucose transport is mediated by a Ca²⁺-dependent mechanism in slow-twitch rat soleus muscle. American Journal of Physiology. Endocrinology and Metabolism 288 E1062–E1066.
122. ↵
     1. Wu X,
     2. Motoshima H,
     3. Mahadev K,
     4. Stalker TJ,
     5. Scalia R &
     6. Goldstein BJ

     2003 Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52 1355–1363.
123. ↵
     1. Xiao B,
     2. Heath R,
     3. Saiu P,
     4. Leiper FC,
     5. Leone P,
     6. Jing C,
     7. Walker PA,
     8. Haire L,
     9. Eccleston JF,
     10. Davis CT
     11. et al.

     2007 Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 449 496–500.
124. ↵
     1. Xue B &
     2. Kahn BB

     2006 AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. Journal of Physiology 574 73–83.
125. ↵
     1. Yamauchi T,
     2. Kamon J,
     3. Minokoshi Y,
     4. Ito Y,
     5. Waki H,
     6. Uchida S,
     7. Yamashita S,
     8. Noda M,
     9. Kita S,
     10. Ueki K
     11. et al.

     2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 8 1288–1295.
126. ↵
     1. Yu X,
     2. McCorkle S,
     3. Wang M,
     4. Lee Y,
     5. Li J,
     6. Saha AK,
     7. Unger RH &
     8. Ruderman NB

     2004 Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia 47 2012–2021.
127. ↵
     1. Zang M,
     2. Zuccollo A,
     3. Hou X,
     4. Nagata D,
     5. Walsh K,
     6. Herscovitz H,
     7. Brecher P,
     8. Ruderman NB &
     9. Cohen RA

     2004 AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. Journal of Biological Chemistry 279 47898–47905.
128. ↵
     1. Zbucki RL,
     2. Sawicki B,
     3. Hryniewicz A &
     4. Winnicka MM

     2008 Cannabinoids enhance gastric X/A-like cells activity. Folia Histochemistry and Cytobiology 46 219–224.
129. ↵
     1. Zheng D,
     2. MacLean PS,
     3. Pohnert SC,
     4. Knight JB,
     5. Olson AL,
     6. Winder WW &
     7. Dohm GL

     2001 Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. Journal of Applied Physiology 91 1073–1083.
130. ↵
     1. Zhou G,
     2. Myers R,
     3. Li Y,
     4. Chen Y,
     5. Shen X,
     6. Fenyk-Melody J,
     7. Wu M,
     8. Ventre J,
     9. Doebber T,
     10. Fujii N
     11. et al.

     2001 Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 108 1167–1174.
131. ↵
     1. Zong H,
     2. Ren JM,
     3. Young LH,
     4. Pypaert M,
     5. Mu J,
     6. Birnbaum MJ &
     7. Shulman GI

     2002 AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. PNAS 99 15983–15987.